Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria: * Male and female subjects 20 years of age and older. * Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or anti-diabetic agents as monotherapy or combination therapy. * Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit. * Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test. * Willing to participate and give written informed consent. Exclusion Criteria: * Previous exposure to exenatide (anti-exenatide antibodies at screening) or a glucagon-like peptide (GLP-1) analogue. * Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening. * Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry. * Severe renal impairment (creatinine clearance \<30 ml/min) or end stage renal disease.